ReviewSeminars in immunology2011
Immune intervention in type 1 diabetes.
Review in Seminars in immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.Diabetologia · 2020Trial
- Particle-Based therapies for antigen specific treatment of type 1 diabetes.International journal of pharmaceutics · 2023Review
- Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes.Journal of autoimmunity · 2020Article
- Mulberry Leaf Regulates Differentially Expressed Genes in Diabetic Mice Liver Based on RNA-Seq Analysis.Frontiers in physiology · 2018Article
- Tolerogenic Nanoparticles to Treat Islet Autoimmunity.Current diabetes reports · 2017Review
- Treatment of Diabetes Mellitus Using iPS Cells and Spice Polyphenols.Journal of diabetes research · 2017Review
- Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.Current diabetes reports · 2016Review
- IL-Y, a synthetic member of the IL-12 cytokine family, suppresses the development of type 1 diabetes in NOD mice.European journal of immunology · 2015Article
- Type 1 diabetes: A predictable disease.World journal of diabetes · 2015Review
- Selective immunotargeting of diabetogenic CD4 T cells by genetically redirected T cells.Immunology · 2014Article
- A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes.Nature medicine · 2014Article
- Type 1 diabetes.Lancet (London, England) · 2014Review
- Targeting the trimolecular complex.Clinical immunology (Orlando, Fla.) · 2013Review
- Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.Clinical and experimental medicine · 2013Review
- Inducing immune tolerance: a focus on Type 1 diabetes mellitus.Diabetes management (London, England) · 2013Article
- Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention.Diabetes technology & therapeutics · 2013Article
- The Missing Heritability in T1D and Potential New Targets for Prevention.Journal of diabetes research · 2013Article
- Autologous regulatory T cells for the treatment of type 1 diabetes.Current diabetes reports · 2012Review
- Regulation of mesenchymal stem cell differentiation and insulin secretion by differential expression of Pdx-1.Molecular biology reports · 2012Article
- Treating human autoimmunity: current practice and future prospects.Science translational medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type 1 diabetes (T1D) is a chronic autoimmune disease that results in the specific immune destruction of insulin producing beta cells. Currently there is no cure for T1D and treatment for the disease consists of lifelong administration of insulin. Immunotherapies aimed at preventing beta cell destruction in T1D patients with residual c-peptide or in individuals developing T1D are being evaluated. Networks of researchers such as TrialNet and the Immune Tolerance Network in the U.S. and similar networks in Europe have been established to evaluate such immunotherapies. This review focuses on immune intervention for the prevention and amelioration of human T1D with a focus on potential immune suppressive, antigen specific and environmental therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.